Table 1.
Baseline characteristics of the study population.
| Variable | Training | p Value | Validation | p Value | ||
|---|---|---|---|---|---|---|
| Responders (n = 27) |
Non-Responders (n = 17) |
Responders (n = 15) |
Non-Responders (n = 8) |
|||
| Age (years) | 58.33 ± 1.38 | 56.47 ± 2.94 | 0.572 | 66.40 ± 9.60 | 64.12 ± 16.10 | 0.722 |
| Gender | 0.185 | 0.057 | ||||
| Male | 22 (66.7%) | 11 (33.3%) | 5 (45.5%) | 6 (54.5%) | ||
| Female | 5 (45.5%) | 6 (54.5%) | 10 (83.3%) | 2 (16.7%) | ||
| Tumor length (cm) | 58.81 ± 17.99 | 68.88 ± 11.60 | 0.04 * | 62.06 ± 15.01 | 61.50 ± 13.89 | 0.929 |
| Tumor differentiation grade | 0.01 * | 0.149 | ||||
| Well differentiated | 15 (83.3%) | 3 (16.7%) | 5 (83.3%) | 1 (16.7%) | ||
| Moderately differentiated | 11 (55.0%) | 9 (45.0%) | 9 (69.2%) | 4 (30.8%) | ||
| Poor differentiated | 1 (16.7%) | 5 (83.3%) | 1 (25.0%) | 3 (75.0%) | ||
| Clinical tumor stage (cT) | 0.907 | 0.779 | ||||
| T2 | 4 (66.7%) | 2 (33.3%) | 2 (50%) | 2 (50%) | ||
| T3 | 19 (59.4%) | 13 (40.6%) | 11 (68.8%) | 5 (31.2%) | ||
| T4 | 4 (66.7%) | 2 (33.3%) | 2 (66.7%) | 1 (33.3%) | ||
| Clinical nodal stage (cN) | 0.3 | 0.757 | ||||
| N1 | 8 (72.7%) | 3 (27.3%) | 8 (66.7%) | 4 (33.3%) | ||
| N2 | 19 (57.6%) | 14 (42.4%) | 7 (63.6%) | 4 (36.4%) | ||
| MRF | 0.024 * | 0.679 | ||||
| Positive | 4 (33.3%) | 8 (66.7%) | 10 (62.5%) | 6 (37.5%) | ||
| Negative | 23 (71.9%) | 9 (28.1%) | 5 (71.4%) | 2 (28.6%) | ||
* Statistically significant p < 0.05; results are presented as the mean ± standard deviation or number (%).